Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence

Steve Shoptaw, Keith G. Heinzerling, Erin Rotheram-Fuller, Uyen H. Kao, Pin Chieh Wang, Michelle A. Bholat, Walter Ling

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)13-23
Number of pages11
JournalJournal of Addictive Diseases
Volume27
Issue number1
DOIs
StatePublished - Feb 27 2008
Externally publishedYes

Fingerprint

Bupropion
Cocaine-Related Disorders
Cognitive Therapy
Placebos
Cocaine
Therapeutics
Dopamine Uptake Inhibitors
Aptitude
Norepinephrine
Outpatients
Urine
Depression
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Bupropion hydrochloride
  • Cocaine dependence
  • Randomized controlled trial
  • Zyban

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. / Shoptaw, Steve; Heinzerling, Keith G.; Rotheram-Fuller, Erin; Kao, Uyen H.; Wang, Pin Chieh; Bholat, Michelle A.; Ling, Walter.

In: Journal of Addictive Diseases, Vol. 27, No. 1, 27.02.2008, p. 13-23.

Research output: Contribution to journalArticle

Shoptaw, Steve ; Heinzerling, Keith G. ; Rotheram-Fuller, Erin ; Kao, Uyen H. ; Wang, Pin Chieh ; Bholat, Michelle A. ; Ling, Walter. / Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. In: Journal of Addictive Diseases. 2008 ; Vol. 27, No. 1. pp. 13-23.
@article{c37b4a9c6a7342ef9b51b004224a8478,
title = "Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence",
abstract = "Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.",
keywords = "Bupropion hydrochloride, Cocaine dependence, Randomized controlled trial, Zyban",
author = "Steve Shoptaw and Heinzerling, {Keith G.} and Erin Rotheram-Fuller and Kao, {Uyen H.} and Wang, {Pin Chieh} and Bholat, {Michelle A.} and Walter Ling",
year = "2008",
month = "2",
day = "27",
doi = "10.1300/J069v27n01_02",
language = "English (US)",
volume = "27",
pages = "13--23",
journal = "Journal of Addictive Diseases",
issn = "1055-0887",
publisher = "Routledge",
number = "1",

}

TY - JOUR

T1 - Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence

AU - Shoptaw, Steve

AU - Heinzerling, Keith G.

AU - Rotheram-Fuller, Erin

AU - Kao, Uyen H.

AU - Wang, Pin Chieh

AU - Bholat, Michelle A.

AU - Ling, Walter

PY - 2008/2/27

Y1 - 2008/2/27

N2 - Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.

AB - Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.

KW - Bupropion hydrochloride

KW - Cocaine dependence

KW - Randomized controlled trial

KW - Zyban

UR - http://www.scopus.com/inward/record.url?scp=46449103898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46449103898&partnerID=8YFLogxK

U2 - 10.1300/J069v27n01_02

DO - 10.1300/J069v27n01_02

M3 - Article

C2 - 18551884

AN - SCOPUS:46449103898

VL - 27

SP - 13

EP - 23

JO - Journal of Addictive Diseases

JF - Journal of Addictive Diseases

SN - 1055-0887

IS - 1

ER -